Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
DYN Quote, Financials, Valuation and Earnings
Last price:
$15.23
Seasonality move
:
-2.65%
Day range:
$14.41 - $15.56
52-week range:
$6.36 - $25.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.58x
Volume:
1.7M
Avg. volume:
1.9M
1-year change:
28.09%
Market cap:
$2.5B
Revenue:
--
EPS (TTM):
-$3.54
Analysts' Opinion
-
Consensus RatingDyne Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $38.31, Dyne Therapeutics, Inc. has an estimated upside of 151.56% from its current price of $15.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing -5.06% downside risk from its current price of $15.23.
Fair Value
-
According to the consensus of 13 analysts, Dyne Therapeutics, Inc. has 151.56% upside to fair value with a price target of $38.31 per share.
DYN vs. S&P 500
-
Over the past 5 trading days, Dyne Therapeutics, Inc. has underperformed the S&P 500 by -5.22% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Dyne Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dyne Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Dyne Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Dyne Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Dyne Therapeutics, Inc. reported earnings per share of -$0.76.
Enterprise value:
1.6B
EV / Invested capital:
1.37x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.75x
EV / Free cash flow:
-3.69x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2M
Return On Assets:
-53.18%
Net Income Margin (TTM):
--
Return On Equity:
-63.13%
Return On Invested Capital:
-55.89%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$2.5M | -$2.2M | -$2M | -$1M | -$521K | |
| Operating Income | -$242.2M | -$343.9M | -$468.2M | -$97.1M | -$116.1M | |
| EBITDA | -$239.7M | -$341.7M | -$466.2M | -$96.1M | -$115.6M | |
| Diluted EPS | -$3.94 | -$3.35 | -$3.54 | -$0.88 | -$0.76 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $382.4M | $265.6M | $129.4M | $659.3M | $1.1B | |
| Total Assets | $425.7M | $306.3M | $165.1M | $691.2M | $1.2B | |
| Current Liabilities | $28.7M | $28.1M | $51.1M | $42.3M | $50.6M | |
| Total Liabilities | $57.5M | $54M | $73.8M | $61.4M | $214.8M | |
| Total Equity | $368.2M | $252.4M | $91.3M | $629.8M | $972.1M | |
| Total Debt | $28.7M | $25.9M | $22.7M | $19.1M | $164.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$188.2M | -$292.4M | -$403.2M | -$84.3M | -$111.8M | |
| Cash From Investing | $83.3M | -$204.1M | -$28.8M | -$16M | $982K | |
| Cash From Financing | $54.3M | $809.9M | $890.3M | $3.6M | $431M | |
| Free Cash Flow | -$188.9M | -$294.7M | -$423.9M | -$85.4M | -$112.3M | |
DYN
Sector
Market Cap
$2.5B
$25.3M
Price % of 52-Week High
60.92%
49.41%
Dividend Yield
0%
0%
Shareholder Yield
-23.96%
-1.6%
1-Year Price Total Return
28.09%
-17.71%
Beta (5-Year)
1.336
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$15.61
200-day SMA
Buy
Level
$15.10
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$15.98
Relative Strength Index (RSI14)
Sell
Level
41.64
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-54.6125
50-day SMA
Sell
Level
$17.44
MACD (12, 26)
Sell
Level
-0.62
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.1343)
Sell
CA Score
(Annual)
Level (-1.093)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.1262)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, DYN has received 11 Buy ratings 2 Hold ratings, and 0 Sell ratings. The DYN average analyst price target in the past 3 months is $38.31.
-
Where Will Dyne Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dyne Therapeutics, Inc. share price will rise to $38.31 per share over the next 12 months.
-
What Do Analysts Say About Dyne Therapeutics, Inc.?
Analysts are divided on their view about Dyne Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dyne Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Dyne Therapeutics, Inc.'s Price Target?
The price target for Dyne Therapeutics, Inc. over the next 1-year time period is forecast to be $38.31 according to 13 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is DYN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dyne Therapeutics, Inc. is a Buy. 11 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DYN?
You can purchase shares of Dyne Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dyne Therapeutics, Inc. shares.
-
What Is The Dyne Therapeutics, Inc. Share Price Today?
Dyne Therapeutics, Inc. was last trading at $15.23 per share. This represents the most recent stock quote for Dyne Therapeutics, Inc.. Yesterday, Dyne Therapeutics, Inc. closed at $15.23 per share.
-
How To Buy Dyne Therapeutics, Inc. Stock Online?
In order to purchase Dyne Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DYN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DYN
Sector
P/E ratio
--
22.85x
PEG ratio
-0.75x
-0.01x
P/B ratio
2.58x
1.78x
Price / LTM sales
--
1.52x
Growth Metrics
DYN
Sector
Revenue growth
--
3.33%
Earnings growth
13.34%
11.64%
Revenue (5-year growth)
--
6.41%
Earnings forecast
-$0.76
-$0.20
Profitability
DYN
Sector
Profitability FY 2025
-$2M
$2.3M
Return on invested capital
-55.89%
-33.31%
Return on assets
-53.18%
-29.79%
Return on equity
-63.13%
-38.98%
Earnings Date
Last Earnings Date
Mar
2
Next Earnings Date
May
7
Estimated Next Earnings Date
Jun
1
Balance Sheet
DYN
Sector
Total cash
$1.1B
$24.1M
Short term investments
$206.8M
$23.8M
Total assets
$1.2B
$70.1M
Long term debt
$164.2M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Sell
40
PSIX alert for Mar 5
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
Sell
49
TREE alert for Mar 4
LendingTree, Inc. [TREE] is up 1.11% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
